Hyperbaric Medicine Unit, Department of Anesthesiology and Pain Medicine, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Department of Anesthesiology and Pain Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Pain Res Manag. 2021 Apr 22;2021:8817504. doi: 10.1155/2021/8817504. eCollection 2021.
Chronic neuropathic pain is a condition affecting an increasing proportion of the general population and its management requires a comprehensive, multidisciplinary program. A growing body of evidence supports the use of hyperbaric oxygen therapy (HBOT) in several chronic neuropathic pain conditions; however, its role and efficacy remain unclear.
To summarize current evidence for the mechanistic rationale of HBOT in chronic neuropathic pain conditions and to evaluate its clinical efficacy.
This narrative review was conducted after searching the following databases (Medline, Embase, Cochrane, PsycINFO, the Web of Science, Scopus, ClinicalTrials. gov, WHO ICTRP, and ProQuest Digital Dissertation) from January 1946 to March 2020. Articles published in English that involved either animal or human studies with acute or chronic neuropathic pain evaluating any HBOT-related intervention were included.
A total of 2971 citations were identified. A total of 29 studies were included in this review. The mechanisms of action for HBOT use in neuropathic conditions included the primary effects of hyperoxia and edema resolution, as well as the secondary effects pertinent to the production of oxygen and nitrogen reactive species (serving as pain signaling molecules), nitric oxide-dependent release of opioid peptides, and reduction of inflammatory mediators. A robust evidence for HBOT use in the clinical setting was associated with chronic regional pain syndrome and chronic primary bladder pain syndrome. Some evidence supported its use for chronic secondary (peripheral) neuropathic pain including radiation-induced plexus neuropathies, postherpetic neuralgia, and trigeminal neuralgia.
HBOT has been shown to have antinociceptive and analgesic effects in animal models of inflammatory, neuropathic, and chronic pain. Human studies demonstrated beneficial effects of HBOT in improving clinical outcomes such as pain scores, pain-related symptoms, and quality of life. A systematic methodology of HBOT application is necessary to confirm its safety and efficacy.
慢性神经性疼痛是一种影响越来越多人群的病症,其治疗需要一个全面的多学科方案。越来越多的证据支持高压氧治疗(HBOT)在几种慢性神经性疼痛病症中的应用;然而,其作用和疗效仍不清楚。
总结 HBOT 治疗慢性神经性疼痛病症的机制原理的现有证据,并评估其临床疗效。
本叙述性综述在检索了以下数据库(Medline、Embase、Cochrane、PsycINFO、Web of Science、Scopus、ClinicalTrials.gov、WHO ICTRP 和 ProQuest Digital Dissertation)后进行,检索时间为 1946 年 1 月至 2020 年 3 月。纳入了涉及急性或慢性神经性疼痛的动物或人类研究的英文文章,评估了任何与 HBOT 相关的干预措施。
共确定了 2971 条引文。本综述共纳入 29 项研究。HBOT 治疗神经性疾病的作用机制包括:氧合作用和水肿消退的主要作用,以及与氧和氮活性物质(作为疼痛信号分子)产生、一氧化氮依赖性阿片肽释放和炎症介质减少有关的次要作用。大量证据表明 HBOT 在慢性区域性疼痛综合征和慢性原发性膀胱疼痛综合征的临床应用中是有效的。一些证据支持其在慢性继发性(周围)神经性疼痛中的应用,包括放射性臂丛神经病、带状疱疹后神经痛和三叉神经痛。
HBOT 已被证明在炎症性、神经性和慢性疼痛的动物模型中具有镇痛和镇痛作用。人体研究表明,HBOT 改善疼痛评分、疼痛相关症状和生活质量等临床结局的效果有益。需要一种系统的 HBOT 应用方法来确认其安全性和疗效。